Polivy (Polatuzumab Vedotin-piiq)

US Brand Name(s): Polivy

Use in Cancer Treatment

Polatuzumab vedotin-piiq is to treat the adults with diffuse large B-cell lymphoma who have relapsed or whose cancer has not improved following at least two previous treatments. It can also be in combination with rituximab and bendamustine hydrochloride.

The FDA’s Accelerated Approval Program has authorized this usage. A confirmatory trial(s) must prove that polatuzumab vedotin-piiq offers a therapeutic benefit in these individuals as a condition of approval.

Polatuzumab vedotin-piiq is also under research for use in the treatment of various cancers.

Detailed scientific definition – Definition from the NCI Drug Dictionary 

Polatuzumab Vedotin-piiq 

A summary of key facts regarding this medication in layman’s terms, which may contain the following:

  • Cautions about this medicine
  • What is the use and how?
  • Whom should you consult before taking it?
  • What you should know about it before using it?
  • Other drugs that might interact with it
  • Possible negative effects

Drugs are frequently under research to see whether they can assist treat or prevent conditions other than those already prevalent. This patient information leaflet covers uses which have been under authorization. Much of the material, though, might also apply to authorized uses that are being investigated.